These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2192852)

  • 21. Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus.
    Marrero DG
    Clin Cornerstone; 2007; 8(2):33-40; discussion 41-3. PubMed ID: 18357954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine.
    Riddle MC
    Horm Metab Res; 1996 Sep; 28(9):430-3. PubMed ID: 8911978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring the role of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus.
    Graham JP; Stam D
    Pharm Pract Manag Q; 1997 Oct; 17(3):1-9. PubMed ID: 10173306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of non-insulin-dependent diabetes mellitus with metformin.
    Guthrie R
    J Am Board Fam Pract; 1997; 10(3):213-21. PubMed ID: 9159660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combined insulin and sulfonylurea treatment in diabetes mellitus].
    Ravina A; Minuhin O
    Harefuah; 1986 Jan; 110(1):11-4. PubMed ID: 3514394
    [No Abstract]   [Full Text] [Related]  

  • 26. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sulfonylureas in NIDDM.
    Groop LC
    Diabetes Care; 1992 Jun; 15(6):737-54. PubMed ID: 1600834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sulfonylureas.
    Zimmerman BR
    Endocrinol Metab Clin North Am; 1997 Sep; 26(3):511-22. PubMed ID: 9314012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 1998 Oct; 32(10):1044-52. PubMed ID: 9793597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.
    Goo AK; Carson DS; Bjelajac A
    J Fam Pract; 1996 Jun; 42(6):612-8. PubMed ID: 8656173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
    Del Prato S; Pulizzi N
    Metabolism; 2006 May; 55(5 Suppl 1):S20-7. PubMed ID: 16631807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational use of sulfonylureas.
    Davidson MB
    Postgrad Med; 1992 Aug; 92(2):69-70, 73-6, 79-85. PubMed ID: 1495885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy.
    Brown DL; Brillon D
    J Natl Med Assoc; 1999 Jul; 91(7):389-95. PubMed ID: 10643211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes care: what should we try to achieve?
    O'Connor PJ
    J Fam Pract; 1991 Oct; 33(4):343-4. PubMed ID: 1919448
    [No Abstract]   [Full Text] [Related]  

  • 35. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
    Feinglos MN; Thacker CH; English J; Bethel MA; Lane JD
    Diabetes Care; 1997 Oct; 20(10):1539-42. PubMed ID: 9314631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
    Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [40 years of using sulfonylurea derivatives for treatment of diabetes].
    Sieradzki J
    Przegl Lek; 1996; 53(9):641-6. PubMed ID: 8992529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes.
    Tan MH; Glazer NB; Johns D; Widel M; Gilmore KJ
    Curr Med Res Opin; 2004 May; 20(5):723-8. PubMed ID: 15140339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.
    Yki-Järvinen H
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S77-81. PubMed ID: 12324990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.